

Chugai Pharma UK LTD and Chugai Pharma Europe LTD believe it is important to be transparent regarding interactions with Health Care Professionals and Health Care Organisations.

- Patients benefit from the collaboration between Health Care Professionals and the pharmaceutical industry through the development and appropriate use of innovative treatments that improve and extend life.
- Health Care Professionals and pharmaceutical companies regularly work together from early scientific research and clinical trial programmes to the use of medicines in the patient pathway.
- As an integral part of the medicines development process it is entirely appropriate that fees are paid to Health Care Professionals to reimburse them for their time and expertise.
- The pharmaceutical industry is committed to ensuring the transparency of relationships with Health Care Professionals. Across Europe the industry has announced its intention to disclose payments to Health Care Professionals at an individual level by 2016 for payments made in 2015 onwards.
- As part of this journey, in 2013, ABPI member companies are taking the early step of disclosing the total figure paid to all Health Care Professionals during 2013, plus the number of Health Care Professionals that received payments (<http://www.abpi.org.uk>).
- The Ethical Standards in Health and Life Sciences Group (ESHLSG), a group of twenty organisations working together to improve how Health Care Professionals and the pharmaceutical and life sciences industries work together, is consulting on approaches to disclosure payments to Health Care Professionals at an individual level. The consultation can be accessed at <http://www.eshlsg.org>.

On this page you can find information regarding:

1. [Support and interactions with Patient Groups](#)
2. [Donations to Health Care Organisations](#)
3. [Support for Health Care Professionals attending third party organised meetings](#)
4. [Monies paid to Health Care Professionals we engaged for services](#)
5. [Joint Working arrangements](#)

The amount indicated represent spend in the UK for the whole of 2013. The data has been sourced from all Chugai businesses.

The amounts indicated excludes money spent by our partners where we co-promote products.

The amounts shown are inclusive of VAT and taxes where this is applicable.

For further information please contact compliance@chugai-pharm.co.uk

Roche Products LTD and Chugai Pharma UK LTD have a co-promotion agreement in place for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements, each company will independently disclose payments associated with this co-promotion. To view Roche Products Ltd payments, please click on this [link](#)

1. Interactions with Patient Groups:

Listed on this page you will find all interactions that Chugai Pharma UK has had with Patient Groups during 2013. This includes financial donations to help with the service provided to patients, carers and family members. The projects listed also include those where Chugai has worked in partnership with the Patient Groups on specific projects.

Chugai Pharma UK Ltd has made every effort to ensure the accuracy of this data.

Name Of Patient Organisation	Nature of interaction	Value of support
Lymphoma Association	Exhibition stand space at Lymphoma Association Congress 2013	£618
Total		£618

2. Donations to Health Care Organisations:

Listed on this page you will find donations which Chugai made to Health Care Organisations during 2013.

Chugai is proud to support a variety of NHS projects. All applications for funding are rigorously scrutinised to ensure they are intended to enhance patients care or medical education.

Chugai have made every effort to ensure the accuracy of this data.

Name of organisation	Amount provided	Details of project supported
University College London	£5,000	Donation to University College London to ensure effective co-ordination and management of a local investigator initiated study in Chronic Lymphocytic Leukaemia titled 'A pilot study to establish the safety and efficacy of a combination of Dexamethasone and low dose Lenalidomide (D+L) in patients with relapsed or refractory CLL'
University of Liverpool	£6,000	Donation to The University of Liverpool to assist with the effective delivery of the phase III NCRI RIAItO trial (a Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with chronic lymphocytic leukaemia (CLL)) and support the UK CLL Trials Biobank
James Paget University Hospital NHS Trust General Fund	£5,000	An unrestricted donation to the Haematology Department to support staff development and education
Cure Leukaemia Charity	£15,000 x 2 payments	Cure Leukaemia is helping to bring pioneering drug and transplant treatments to blood cancer patients in the Midlands. The charity part-finances

<p>The Blood Cancer Charity</p> <p>Registered Charity Number: 1100154</p>		<p>the world class Centre for Clinical Haematology at QE Hospital Birmingham, to fund life-saving clinical trials to treat terminally ill leukaemia patients. To date Cure Leukaemia has helped to treat thousands of patients through leveraging nearly £21m worth of revolutionary drugs and funding crucial research nurses to administer these trials.</p> <p>Without expert research nurses to ensure patients are constantly monitored and cared for, these trials cannot run. The aim of Cure Leukaemia is to raise money to fund more research nurses at centres across the Midlands. Only by funding more nurses in more hospitals, can more leukaemia patients get access to potentially life- saving treatment.</p> <p>Currently Cure Leukaemia has nurses based at QE Birmingham, Birmingham Children’s Hospital, Sandwell and Dudley, Stoke, Worcester, Coventry and Warwickshire.</p> <p>“This donation will enable the ongoing support of clinical nurses at the Centre of Clinical Haematology who lead a broad range of leukaemia and lymphoma studies.”</p>
<p>University College London</p>	<p>£3000</p>	<p>Exhibition stand cost for 43rd Annual Lymphoma Trials Meeting, 25th October 2013</p>
<p>Queen Mary University Hospital</p>	<p>£20,000</p>	<p>Grant to ensure effective co-ordination and management of a local investigator initiated study titled The Regenerate Cardiac Stem Cell Trials held at Queen Mary University Hospital</p>

Royal National Hospital for Rheumatic diseases	£492	Health Promotion Day, June 2013
Department of Rheumatology, Luton & Dunstable NHS Foundation Trust	£300	Health Promotion Day. Payment covers catering costs

3. Support for Health Care Professionals attending third party organised meetings

An important aspect of being a Health Care Professional is to retain high knowledge and skill levels in the relevant therapy areas. Chugai is pleased to support Health Care Professionals to enhance their knowledge and experience to allow them to attend educational meetings which will ensure the highest quality and most up-to-date knowledge to the benefit of patient care.

	Number of sponsored delegates	Aggregate amount of sponsorship provided
Total costs	87	£23,421
Registration fees (UK & overseas meetings)	48	£15,109
All Accommodation (UK & Overseas meetings)	19	£3420
Overseas travel	2	£640

4. Monies paid to Health Care Professionals we engage for services

Chugai Pharma UK LTD, Chugai Pharma Marketing LTD, Chugai Pharma Europe LTD and Chugai Pharmaceuticals, Japan regularly commission services from Health Care Professionals. For example, we may commission specialists to speak at educational meetings attended by other Health Care Professionals. When we do so it is appropriate to reimburse the speakers for their time in preparing and presenting material.

Below is a list of monies which Chugai has paid these Health Care Professionals for their services during 2013.

Chugai has made every effort to ensure the accuracy of this data.

Total amount of fees paid out	£91,688
Number of Health Care Professionals (HCPs)	89

5. Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery. Many such projects have been successfully implemented, benefiting patients across the UK.

Chugai Pharma UK will comply with Joint Working policies as defined by the ABPI in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2013
--------------------------------------	--